NASDAQ:TARS Tarsus Pharmaceuticals (TARS) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free TARS Stock Alerts $37.35 -0.68 (-1.79%) (As of 05/8/2024 ET) Add Compare Share Share Today's Range$36.18▼$38.2750-Day Range$29.43▼$38.2952-Week Range$12.57▼$40.40Volume916,036 shsAverage Volume711,147 shsMarket Capitalization$1.41 billionP/E RatioN/ADividend YieldN/APrice Target$48.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Tarsus Pharmaceuticals alerts: Email Address Tarsus Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside29.5% Upside$48.38 Price TargetShort InterestBearish20.91% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.20Based on 4 Articles This WeekInsider TradingSelling Shares$749,578 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.25) to ($2.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.03 out of 5 starsMedical Sector339th out of 905 stocksBiological Products, Except Diagnostic Industry48th out of 154 stocks 4.4 Analyst's Opinion Consensus RatingTarsus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageTarsus Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Tarsus Pharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted20.91% of the outstanding shares of Tarsus Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverTarsus Pharmaceuticals has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.Change versus previous monthShort interest in Tarsus Pharmaceuticals has recently increased by 0.64%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldTarsus Pharmaceuticals does not currently pay a dividend.Dividend GrowthTarsus Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TARS. Previous Next 2.9 News and Social Media Coverage News SentimentTarsus Pharmaceuticals has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Tarsus Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest5 people have searched for TARS on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows4 people have added Tarsus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tarsus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $749,578.00 in company stock.Percentage Held by Insiders11.54% of the stock of Tarsus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions90.01% of the stock of Tarsus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tarsus Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Tarsus Pharmaceuticals are expected to grow in the coming year, from ($4.25) to ($2.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tarsus Pharmaceuticals is -8.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tarsus Pharmaceuticals is -8.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTarsus Pharmaceuticals has a P/B Ratio of 6.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Tarsus Pharmaceuticals Stock (NASDAQ:TARS)Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.Read More TARS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TARS Stock News HeadlinesMay 8, 2024 | investorplace.comTARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | globenewswire.comTarsus Reports First Quarter 2024 Financial Results and Recent Business AchievementsMay 9, 2024 | Porter & Company (Ad)How Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that will forever enshrine Obama’s destructive, Marxist vision for America… A plot that could hand him and his allies near-total control over the government, your way of life, and your future.May 7, 2024 | markets.businessinsider.comTarsus Pharmaceuticals earnings: here's what Wall Street expectsMay 1, 2024 | globenewswire.comTarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024May 1, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Legend Biotech (LEGN), Organon (OGN) and Exelixis (EXEL)April 28, 2024 | latimes.comMaáza MartinApril 25, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Amneal Pharmaceuticals (AMRX) and Community Health (CYH)May 9, 2024 | Porter & Company (Ad)How Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that will forever enshrine Obama’s destructive, Marxist vision for America… A plot that could hand him and his allies near-total control over the government, your way of life, and your future.April 24, 2024 | lse.co.ukBioPharma Credit to loan USD100 million to Tarsus PharmaceuticalsApril 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Tarsus Pharmaceuticals Amidst Strategic Debt Refinancing and Strong Financial OutlookApril 23, 2024 | globenewswire.comTarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from PharmakonApril 19, 2024 | finance.yahoo.comInsider Returns Down To US$166k As Tarsus Pharmaceuticals' Stock Dips 14%April 8, 2024 | finance.yahoo.comWall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should KnowApril 6, 2024 | msn.comScientists share trial results for new tick-repelling drug for humans: 'An amazing opportunity'March 21, 2024 | investing.comTarsus Pharmaceuticals executive sells over $130k in company stockMarch 21, 2024 | investing.comTarsus Pharmaceuticals exec sells over $135k in stockMarch 18, 2024 | msn.comPill Targeting Tick-Induced Lyme Disease Shows Promise in Human TrialsMarch 16, 2024 | finance.yahoo.comTARS Apr 2024 25.000 callMarch 16, 2024 | finance.yahoo.comTARS Apr 2024 17.500 putMarch 16, 2024 | finance.yahoo.comTARS Apr 2024 12.500 callMarch 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: ProQR (PRQR) and Crinetics Pharmaceuticals (CRNX)March 5, 2024 | globenewswire.comTarsus to Participate at Upcoming Investor ConferencesMarch 5, 2024 | globenewswire.comTarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex BlepharitisMarch 2, 2024 | investing.comTarsus Pharmaceuticals launches $100 million stock offeringMarch 1, 2024 | finance.yahoo.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Just Reported Annual Earnings And Analysts Are Lifting Their EstimatesMarch 1, 2024 | msn.comTarsus Pharmaceuticals stock dips after pricing $100M securities offeringSee More Headlines Receive TARS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today5/08/2024Next Earnings (Confirmed)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TARS CUSIPN/A CIK1819790 Webwww.tarsusrx.com Phone949-409-9820FaxN/AEmployees244Year FoundedN/APrice Target and Rating Average Stock Price Target$48.38 High Stock Price Target$59.00 Low Stock Price Target$30.00 Potential Upside/Downside+29.5%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($4.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-135,890,000.00 Net MarginsN/A Pretax Margin-778.89% Return on Equity-74.28% Return on Assets-58.20% Debt Debt-to-Equity Ratio0.15 Current Ratio6.93 Quick Ratio6.85 Sales & Book Value Annual Sales$17.45 million Price / Sales80.86 Cash FlowN/A Price / Cash FlowN/A Book Value$5.95 per share Price / Book6.28Miscellaneous Outstanding Shares37,780,000Free Float33,418,000Market Cap$1.41 billion OptionableOptionable Beta1.10 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Bobak R. Azamian M.D.Co-Founder, President, CEO & ChairmanDr. Bryan Wahl J.D. (Age 46)M.D., General Counsel & Corporate Secretary Comp: $619.09kDr. Elizabeth Yeu Lin M.D. (Age 46)Chief Medical Advisor & Director Comp: $286kMr. Jeffrey S. Farrow (Age 62)CFO & Chief Strategy Officer Dr. Seshadri Neervannan Ph.D. (Age 56)Chief Operating Officer Comp: $486.67kMr. David NakasoneHead of Investor RelationsMs. Adrienne KempSenior Director of Corporate CommunicationsMr. Matthew Rossen M.B.A. (Age 46)Vice President of Marketing Mr. Scott YoumansVice President of SalesMs. Dianne C. Whitfield M.S.W. (Age 47)Chief Human Resources Officer Comp: $578.9kMore ExecutivesKey Competitors4D Molecular TherapeuticsNASDAQ:FDMTVir BiotechnologyNASDAQ:VIRNeumora TherapeuticsNASDAQ:NMRAADMA BiologicsNASDAQ:ADMACullinan OncologyNASDAQ:CGEMView All CompetitorsInsiders & InstitutionsRussell Investments Group Ltd.Bought 29,959 shares on 5/8/2024Ownership: 0.080%Thoroughbred Financial Services LLCBought 20,964 shares on 5/8/2024Ownership: 0.055%ProShare Advisors LLCBought 7,631 shares on 5/8/2024Ownership: 0.020%Bleakley Financial Group LLCBought 6,147 shares on 5/8/2024Ownership: 0.016%Swiss National BankBought 600 shares on 5/7/2024Ownership: 0.112%View All Insider TransactionsView All Institutional Transactions TARS Stock Analysis - Frequently Asked Questions Should I buy or sell Tarsus Pharmaceuticals stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tarsus Pharmaceuticals in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TARS shares. View TARS analyst ratings or view top-rated stocks. What is Tarsus Pharmaceuticals' stock price target for 2024? 8 Wall Street analysts have issued 12 month price targets for Tarsus Pharmaceuticals' stock. Their TARS share price targets range from $30.00 to $59.00. On average, they anticipate the company's share price to reach $48.38 in the next twelve months. This suggests a possible upside of 29.5% from the stock's current price. View analysts price targets for TARS or view top-rated stocks among Wall Street analysts. How have TARS shares performed in 2024? Tarsus Pharmaceuticals' stock was trading at $20.25 at the beginning of 2024. Since then, TARS shares have increased by 84.4% and is now trading at $37.35. View the best growth stocks for 2024 here. How were Tarsus Pharmaceuticals' earnings last quarter? Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) released its quarterly earnings data on Tuesday, February, 27th. The company reported ($1.31) EPS for the quarter, beating analysts' consensus estimates of ($1.37) by $0.06. The company had revenue of $13.08 million for the quarter, compared to analysts' expectations of $4.63 million. During the same period last year, the company posted ($0.49) EPS. What ETFs hold Tarsus Pharmaceuticals' stock? ETFs with the largest weight of Tarsus Pharmaceuticals (NASDAQ:TARS) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and ALPS Medical Breakthroughs ETF (SBIO).iShares U.S. Pharmaceuticals ETF (IHE). When did Tarsus Pharmaceuticals IPO? Tarsus Pharmaceuticals (TARS) raised $80 million in an initial public offering on Friday, October 16th 2020. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Raymond James served as the underwriters for the IPO and LifeSci Capital and Ladenburg Thalmann were co-managers. Who are Tarsus Pharmaceuticals' major shareholders? Tarsus Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (3.52%), Vivo Capital LLC (1.65%), Allspring Global Investments Holdings LLC (0.56%), Raymond James Financial Services Advisors Inc. (0.15%), Swiss National Bank (0.11%) and Sei Investments Co. (0.09%). Insiders that own company stock include Andrew D Goldberg, Aziz Mottiwala, Bobak R Azamian, Bobak R Azamian, Bryan Wahl, Dianne C Whitfield, Elizabeth Yeu Lin, Jose M Trevejo, Leonard M Greenstein, Mark J Holdbrook, Michael Ackermann, Seshadri Neervannan and Vivo Capital Ix, Llc. View institutional ownership trends. How do I buy shares of Tarsus Pharmaceuticals? Shares of TARS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TARS) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressObama’s Forever Term [exposed]Porter & CompanyThe A.I. story nobody is telling you (Read ASAP)TradeSmithExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill Publishing348 million Americans lives to END as we know it?The Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
